Is Alphabet Stock No Longer a Good Bet?
Alphabet tripled its price per share over the past 5…
Buy
59
HCA Quote, Financials, Valuation and Earnings
Last price:
$334.28
Seasonality move
:
2.89%
Day range:
$327.32 - $332.62
52-week range:
$289.98 - $417.14
Dividend yield:
0.82%
P/E ratio:
15.03x
P/S ratio:
1.22x
P/B ratio:
--
Volume:
1M
Avg. volume:
1.7M
1-year change:
0.91%
Market cap:
$81.3B
Revenue:
$70.6B
EPS (TTM):
$21.97
Analysts' Opinion
-
Consensus RatingHCA Healthcare has received a consensus rating of Buy. The company's average rating is a Buy based on 15 Buy ratings, 7 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $374.89, HCA Healthcare has an estimated upside of 13.55% from its current price of $330.16.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $316.00 representing 100% downside risk from its current price of $330.16.
Fair Value
-
According to the consensus of 23 analysts, HCA Healthcare has 13.55% upside to fair value with a price target of $374.89 per share.
HCA vs. S&P 500
-
Over the past 5 trading days, HCA Healthcare has overperformed the S&P 500 by 0.9% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
HCA Healthcare does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
HCA Healthcare has grown year-over-year revenues for 9 quarters straight. In the most recent quarter HCA Healthcare reported revenues of $18.3B.
Earnings Growth
-
HCA Healthcare earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter HCA Healthcare reported earnings per share of $5.63.
Enterprise value:
125.4B
EV / Invested capital:
2.88x
Price / LTM sales:
1.22x
EV / EBIT:
11.85x
EV / Revenue:
1.78x
PEG ratio (5yr expected):
0.95x
EV / Free cash flow:
22.24x
Price / Operating cash flow:
15.33x
Enterprise value / EBITDA:
9.03x
Gross Profit (TTM):
$59.8B
Return On Assets:
9.95%
Net Income Margin (TTM):
8.16%
Return On Equity:
574.85%
Return On Invested Capital:
13.61%
Operating Margin:
15.57%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $60.2B | $65B | $70.6B | $17.3B | $18.3B | |
| Gross Profit | $50.9B | $55.1B | $59.8B | $14.7B | $15.5B | |
| Operating Income | $9.1B | $9.6B | $10.5B | $2.8B | $2.8B | |
| EBITDA | $13.3B | $12.7B | $13.9B | $3.6B | $3.5B | |
| Diluted EPS | $19.23 | $18.98 | $21.97 | $5.93 | $5.63 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $12.3B | $13.5B | $13.6B | $14.9B | $16.4B | |
| Total Assets | $47.5B | $50.7B | $52.4B | $56.2B | $59.5B | |
| Current Liabilities | $8.7B | $9.6B | $9.9B | $12.7B | $15.2B | |
| Total Liabilities | $44.6B | $49.3B | $52.5B | $55.2B | $59B | |
| Total Equity | $2.9B | $1.5B | -$73M | $1.1B | $555M | |
| Total Debt | $31B | $34.6B | $38.1B | $39.6B | $43B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $8.5B | $9.4B | $10.5B | $2.7B | $2.6B | |
| Cash From Investing | -$3.4B | -$5.3B | -$4.9B | -$1.6B | -$1.3B | |
| Cash From Financing | -$5.7B | -$4.1B | -$4.6B | -$1B | -$2.2B | |
| Free Cash Flow | $4.1B | $4.7B | $5.6B | $1.5B | $1.3B | |
HCA
Sector
Market Cap
$81.3B
$37.4M
Price % of 52-Week High
79.15%
45.61%
Dividend Yield
0.82%
0%
Shareholder Yield
7.95%
-0.75%
1-Year Price Total Return
0.91%
-38.36%
Beta (5-Year)
1.681
0.774
Dividend yield:
0.82%
Annualized payout:
$2.64
Payout ratio:
11.98%
Growth streak:
4 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$322.64
200-day SMA
Sell
Level
$345.25
Bollinger Bands (100)
Buy
Level
303.15 - 353.59
Chaikin Money Flow
Buy
Level
271.4M
20-day SMA
Buy
Level
$319.79
Relative Strength Index (RSI14)
Buy
Level
55.58
ADX Line
Buy
Level
15.17
Williams %R
Neutral
Level
-31.8869
50-day SMA
Buy
Level
$318.15
MACD (12, 26)
Buy
Level
1.09
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
348M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.512)
Sell
CA Score
(Annual)
Level (-1.6263)
Buy
Beneish M-Score
(Annual)
Level (-2.7292)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (1.3514)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of June 2024, the firm owned and operated 188 hospitals, 123 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
Stock Forecast FAQ
In the current month, HCA has received 15 Buy ratings 7 Hold ratings, and 1 Sell ratings. The HCA average analyst price target in the past 3 months is $374.89.
-
Where Will HCA Healthcare Stock Be In 1 Year?
According to analysts, the consensus estimate is that HCA Healthcare share price will rise to $374.89 per share over the next 12 months.
-
What Do Analysts Say About HCA Healthcare?
Analysts are divided on their view about HCA Healthcare share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that HCA Healthcare is a Sell and believe this share price will drop from its current level to $316.00.
-
What Is HCA Healthcare's Price Target?
The price target for HCA Healthcare over the next 1-year time period is forecast to be $374.89 according to 23 Wall Street analysts, 15 of them rate the stock a Buy, 1 rates the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is HCA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for HCA Healthcare is a Buy. 15 of 23 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HCA?
You can purchase shares of HCA Healthcare via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase HCA Healthcare shares.
-
What Is The HCA Healthcare Share Price Today?
HCA Healthcare was last trading at $334.28 per share. This represents the most recent stock quote for HCA Healthcare. Yesterday, HCA Healthcare closed at $330.16 per share.
-
How To Buy HCA Healthcare Stock Online?
In order to purchase HCA Healthcare stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Pepsi Vs Coke Stock: Which Is Best?
Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…
Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
52
RGC alert for Mar 19
Regencell Bioscience Holdings [RGC] is down 0.66% over the past day.
Sell
49
SRPT alert for Mar 19
Sarepta Therapeutics [SRPT] is up 8.72% over the past day.
Sell
46
CVNA alert for Mar 19
Carvana [CVNA] is up 5.74% over the past day.
